Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Empasiprubart Versus Intravenous Immunoglobulin in Adults With Multifocal Motor Neuropathy

Next Previous
Trial Profile

A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Empasiprubart Versus Intravenous Immunoglobulin in Adults With Multifocal Motor Neuropathy

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 12 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Empasiprubart (Primary) ; Immunoglobulins
  • Indications Multifocal motor neuropathy
  • Focus Registrational; Therapeutic Use
  • Acronyms Empassion
  • Sponsors argenx

Most Recent Events

  • 13 Jan 2025 According to an argenx SE media releease, registrational EMPASSION study ongoing in MMN evaluating empasiprubart head-to-head versus IVIg, topline results expected in second half of 2026.
  • 13 Jan 2025 Status changed from not yet recruiting to recruiting.
  • 21 Oct 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top